RASVIN BUTTAR: Open Payments
NPI 1104328152 · FRENCH CAMP, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$777 in 31 payments from 15 companies in 2025. Trend: 2023 $661 · 2024 $294 · 2025 $777
Food & beverage: $752Education: $26
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $162 |
| Novartis Pharmaceuticals Corporation | 5 | $119 |
| AstraZeneca Pharmaceuticals LP | 2 | $60 |
| Merck Sharp & Dohme LLC | 2 | $59 |
| ABBVIE INC. | 2 | $55 |
| Incyte Corporation | 2 | $51 |
| Eisai Inc. | 2 | $48 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Napo Pharmaceuticals Inc | 2 | $36 |
| Nuvation Bio Inc. | 1 | $31 |
Products named: RYBREVANT, SCEMBLIX, EPKINLY, LYNPARZA, Lenvima, OPDIVO, GELCLAIR CONCENTRATED ORAL GEL, IMFINZI.
Industry payments across CA — which companies pay providers there.
